Compare ADMA Biologics Inc (ADMA) vs American Financial Group Inc (AFG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs American Financial Group Inc — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while American Financial Group Inc trades at $141.19 (market cap $11.86B). The key difference: American Financial Group Inc is far larger — about 5.6× ADMA Biologics Inc's market cap, and American Financial Group Inc pays a 2.46% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | AFG | |
|---|---|---|
Market Cap | $2.13B | $11.86B |
Sector | Health | Financials |
52-Week High | $20.38 | $148.71 |
52-Week Low | $7.60 | $122.42 |
Enterprise Value | $2.20B | $12.33B |
Dividend Yield | — | 2.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
AFG trades at $142.80, up 0.04% with a bullish technical outlook. The stock shows strong profitability with 10.84% net margin and 19.38% ROE, though Q1 2026 earnings missed estimates. Recent dividend declarations of $0.88 per share highlight shareholder returns. Analyst consensus is mixed with 41% buy ratings and a $149 price target, representing 4.3% upside from current levels.
AFG offers moderate upside potential with solid fundamentals and consistent dividends, but faces execution risks after recent earnings miss. The insurance sector exposure provides stability, though competitive pressures and regulatory changes remain key watchpoints for investors seeking steady returns with income generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About American Financial Group Inc
American Financial Group Inc is a holding company that is engaged primarily in property and casualty insurance services. The company has a focus on specialized commercial products for businesses. American also has annuity operations that are focused on sales of traditional fixed and fixed-indexed annuities in the education, bank, and individual markets. American's insurance operations are conducted through the Great American Insurance Group. The group writes business in all 50 of the United States, primarily through independent agents and brokers.
Read more on AFG →
